Who are Tirofiban+Oral Dual Antiplatelet Therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Abciximab + UFH, Bivalirudin with and without eptifibatide, Glycoprotein IIb/IIIa inhibitors, abciximab intravenously, Intravenous tirofiban before endovascular thrombectomy, Eptifibatide Injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tirofiban-oral-dual-antiplatelet-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Tirofiban+Oral Dual Antiplatelet Therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tirofiban+Oral Dual Antiplatelet Therapy (Tirofiban+Oral Dual Antiplatelet Therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glycoprotein IIb/IIIa inhibitor + Dual antiplatelet therapy. Area: Cardiovascular.

marketed Glycoprotein IIb/IIIa inhibitor + Dual antiplatelet therapy Glycoprotein IIb/IIIa receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Tirofiban+Oral Dual Antiplatelet Therapy (Tirofiban+Oral Dual Antiplatelet Therapy) — Second Affiliated Hospital of Soochow University. Tirofiban is a glycoprotein IIb/IIIa inhibitor combined with oral dual antiplatelet therapy to prevent platelet aggregation and thrombotic events through multiple antiplatelet pathways.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tirofiban+Oral Dual Antiplatelet Therapy TARGET	Tirofiban+Oral Dual Antiplatelet Therapy	Second Affiliated Hospital of Soochow University	marketed	Glycoprotein IIb/IIIa inhibitor + Dual antiplatelet therapy	Glycoprotein IIb/IIIa receptor
Abciximab + UFH	Abciximab + UFH	Deutsches Herzzentrum Muenchen	marketed	Glycoprotein IIb/IIIa inhibitor (in combination with anticoagulant)	Platelet glycoprotein IIb/IIIa receptor
Bivalirudin with and without eptifibatide	Bivalirudin with and without eptifibatide	LifeBridge Health	marketed	Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide)	Thrombin (Factor IIa) and Glycoprotein IIb/IIIa receptor
Glycoprotein IIb/IIIa inhibitors	Glycoprotein IIb/IIIa inhibitors	University of Luebeck	marketed	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa receptor
abciximab intravenously	abciximab intravenously	University of Leipzig	phase 3	GP IIb/IIIa inhibitor	Glycoprotein IIb/IIIa receptor
Intravenous tirofiban before endovascular thrombectomy	Intravenous tirofiban before endovascular thrombectomy	General Hospital of Shenyang Military Region	phase 3	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa receptor
Eptifibatide Injection	Eptifibatide Injection	Ministry of Science and Technology of the People´s Republic of China	phase 3	Glycoprotein IIb/IIIa inhibitor	Glycoprotein IIb/IIIa receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glycoprotein IIb/IIIa inhibitor + Dual antiplatelet therapy class)

Second Affiliated Hospital of Soochow University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tirofiban+Oral Dual Antiplatelet Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/tirofiban-oral-dual-antiplatelet-therapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab